Basecamp Wealth Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.72M Hold
10,959
0.32% 36
2026
Q1
$1.67M Hold
10,959
0.35% 30
2025
Q4
$1.51M Buy
+10,959
New +$1.44M 0.32% 31

Other funds holding NVS

Basecamp Wealth Advisors's NVS Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Novartis (NVS) position steady in Q2 2026 at 10,959 shares worth $1.72M. The position accounts for 0.32% of the portfolio, ranked #36.

Basecamp Wealth Advisors first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,608 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Basecamp Wealth Advisors held 10,959 shares of Novartis worth $1.72M as of Q2 2026.
  • Basecamp Wealth Advisors left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.32% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #36 holding.
  • Basecamp Wealth Advisors first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
  • 1,608 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.